Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy with Valspodar and/or Aldesleukin in AML
NCT00006363Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2000
- Primary completion
- Jun 2005
- Modality
- Cytokines & Interferons, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valspodar and aldesleukin in acute myeloid leukemia (AML) (4 arms), sponsored by National Cancer Institute. Primary endpoints: Disease-Free Survival up to 10 years and Overall Survival up to 10 years. Started Nov 2000; status: completed.
02
Drugs
valspodaraldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00006363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006363.